Serum Glutamate Is a Predictor for the Diagnosis of Multiple Sclerosis

Abstract EN

One neurotransmitter, glutamate, has been implicated in the autoimmune demyelination seen in multiple sclerosis (MS).

Glutamate is present in many tissues in the body, so consideration should be given to whether the serum level of glutamate is likely well correlated with the activity of the disease.

This research aimed to compare the serum glutamate levels from patients diagnosed with MS with those from an age-matched control population.

A review of this data could shed light upon whether the serum testing of glutamate using Enzyme-Linked Immunosorbent Assay (ELISA) is a reliable indicator of MS activity.

Serum samples were obtained from 55 patients with different patterns of MS and from 25 healthy adults as a control group.

The ELISA technique was used to determine the glutamate levels in the serum samples.

The mean serum glutamate level for patients with MS was 1.318±0.543 nmol/ml and that of the controls was 0.873±0.341 nmol/ml.

The serum glutamate levels showed an area under the curve via the receiver operating characteristics (ROC) of 0.738, which was significant (p value = 0.001).

The present study is the first to establish a strong connection between the serum glutamate levels and MS patients, where there was statistically significant elevation of serum glutamate in MS patients; hence this elevation might be used as a monitor to help in the diagnosis of MS patients.